BioTie Therapies Corp. Completes Planned Portfolio Review  
9/24/2013 9:18:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Biotie Therapies Corp., a specialized drug development company focused on neurodegenerative and psychiatric disorders, today announces the outcome of its planned portfolio review following its success earlier in the year with the approval and launch of Selincro® in Europe by H. Lundbeck A/S ("Lundbeck") and the exercise by UCB S.A. ("UCB") of its license for tozadenant (SYN115), for which Biotie received a USD 20 million milestone.

Help employers find you! Check out all the jobs and post your resume.